康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 05-06 16:08:10

133.500

+5.700

+4.46%

最高135.000	最低126.100	成交量1,376万
今开126.100	昨收127.800	日振幅6.96%
总市值1,230亿	流通市值1,230亿	总股本9.21亿
成交额18.19亿	换手率1.49%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":133.5,"timestamp":1778054890009,"preClose":127.8,"halted":0,"volume":13764208,"delay":0,"changeRate":0.044600938967136176,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"未开盘","change":5.7,"latestTime":"05-06 16:08:10","open":126.1,"high":135,"low":126.1,"amount":1818713652,"amplitude":0.06964,"askPrice":133.8,"askSize":61000,"bidPrice":133.5,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.37184,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":127.8,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":2.371167,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.4438,"impliedVolPercentile":0.0845},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1103227376","title":"康方生物4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1103227376","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103227376?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:11","pubTimestamp":1778055085,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年5月6日公布截至2026年4月30日的股份变动月报表。报告显示，公司法定股本维持在5,000,000,000股普通股不变，每股面值USD 0.00001，总计USD 50,000。截至报告期末，公司已发行及流通在外普通股数量为921,143,176股，与上月底一致，库藏股数量为0股。据公布信息，截至2026年4月30日，公司满意香港联交所最低公众持股量要求，股本结构保持稳定。据月报显示，本次公告由公司董事夏瑜签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145664835","title":"异动解读 | 市场重新评估临床试验影响，康方生物盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145664835","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145664835?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:37","pubTimestamp":1778035037,"startTime":"0","endTime":"0","summary":"康方生物今日盘中大涨5.01%，引起了市场的广泛关注。消息面上，此次上涨主要源于市场对前期超跌的重新评估。此外，华福证券维持对康方生物的“买入”评级，并通过DCF模型测算其合理股价为206港元，指出当前股价仍存在较大的折价空间。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633971402","title":"港股异动 | 康方生物(09926)早盘涨超5% 机构仍看好ivonescimab击败K药","url":"https://stock-news.laohu8.com/highlight/detail?id=2633971402","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633971402?lang=zh_cn&edition=full","pubTime":"2026-05-06 09:45","pubTimestamp":1778031943,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)早盘涨超5%，截至发稿，涨5.48%，报134.8港元，成交额5.55亿港元。消息面上，4月30日，康方生物合作伙伴Summit Therapeutics披露，PD-1/VEGF双抗ivonescimab的三期HARMONi-3研究未按计划获得中期无进展生存期（PFS）结果。中信证券（香港）表示，研究指出此次未达预期仅反映ivonescimab在预设严苛标准下未能在中期阶段显著超越Keytruda。分析强调，基于HARMONi-6的经验，预计在2026年下半年HARMONi-3中正常且较宽松的alpha分配下，该药有信心击败Keytruda。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999002224.SGD","BK4007","LU0985320562.USD","LU2106854487.HKD","LU2023250843.SGD","IE00B2B36J28.USD","LU2125154935.USD","BK1574","LU0432979614.USD","IE0002141913.USD","LU0477156953.USD","BK4534","LU1066051225.USD","SG9999014567.USD","LU0098860793.USD","LU0234572021.USD","LU0561508036.HKD","LU1069347547.HKD","LU2468319806.SGD","LU2361045086.USD","LU0417516902.SGD","LU0106261372.USD","LU0320765489.SGD","LU2476274308.USD","BK4533","LU0348825331.USD","LU2361044949.HKD","LU0417516571.SGD","LU2491050154.USD","BK4516","LU0965509283.SGD","LU0348766576.USD","LU1941712264.USD","LU0058720904.USD","LU2324357040.USD","LU1571399168.USD","LU0265550359.USD","IE000M9KFDE8.USD","LU1974910355.USD","LU1934455277.USD","IE00B4R5TH58.HKD","BK4550","LU2399975544.HKD","LU0965508806.USD","LU1037948897.HKD","LU2357627491.SGD","LU2491049909.HKD","LU1794554557.SGD","LU1917777945.USD","LU0417516738.SGD","LU0006306889.USD","LU1430594728.SGD","IE00B1BXHZ80.USD","SGXZ57979304.SGD","LU0289739699.SGD","LU1116320901.HKD","IE00BLSP4239.USD","LU1983299246.USD","LU1989772923.USD","LU1061106388.HKD","LU1023059063.AUD","SG9999015341.SGD","LU1066051811.HKD","IE00BJT1NW94.SGD","LU1699723380.USD","LU2476274720.SGD","LU0859254822.USD","SG9999001176.SGD","LU0348784397.USD","IE00B5MMRT66.SGD","IE00BLSP4452.SGD","LU1934455194.USD","LU1941712348.USD","LU1066051498.USD","LU1929549753.HKD","LU0861579265.USD","IE00B543WZ88.USD","LU0348827113.USD","LU1035773651.USD","LU0320765646.SGD","LU0965509010.AUD","IE00BSNM7G36.USD","LU1093756168.USD","LU2112291526.USD","LU2461242641.AUD","09926","LU0634319403.HKD","LU1162221912.USD","LU2778985437.USD","LU0070302665.USD","IE00BBT3K403.USD","LU0868494708.USD","LU0203345920.USD","LU1291159041.SGD","LU0980610538.SGD","IE00BJJMRZ35.SGD","LU0266013472.USD","LU2491050071.SGD","LU0965509101.SGD","LU0211331839.USD","SG9999002232.USD","SG9999014542.SGD","LU1093756325.SGD","LU2361044865.SGD","LU0868494617.USD","LU0238689110.USD","LU1720050803.USD","LU0348767384.USD","LU2089984988.USD","LU1037948541.HKD","LU2360032135.SGD","LU0122379950.USD","LU1585245621.USD","IE00BN8TJ469.HKD","LU1989772840.SGD","LU0348783233.USD","LU1934455863.HKD","SG9999001440.SGD","LU0540923850.HKD","LU1201861249.SGD","IE00BPRC5H50.USD","LU0130517989.USD","LU0648001328.SGD","SG9999001176.USD","SG9999014559.SGD","SG9999015358.SGD","LU2023250504.SGD","SG9999013999.USD","LU0208291251.USD","SG9999014575.USD","BK4585","LU0265550946.USD","LU0348735423.USD","LU0203347892.USD","LU1961090484.USD","IE0009355771.USD","LU2125154778.USD","BK1161","LU1989771016.USD","LU0130102774.USD","LU1066053197.SGD","IE00BFTCPJ56.SGD","LU1116320737.USD","LU2488822045.USD","LU0942090050.USD","LU1057294990.SGD","BK4559","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632982969","title":"康方生物(09926)下跌8.39% 机构指核心双抗爬坡节奏放缓下调收入预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2632982969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632982969?lang=zh_cn&edition=full","pubTime":"2026-05-04 10:37","pubTimestamp":1777862245,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康方生物 震荡走低，早盘一度跌超10%，截至发稿，最新报124.60港元，下跌8.39%，成交额4.58亿港元。消息面上，华福证券研究指，预计公司2026-2028年营业收入分别为51.10、75.66、122.36亿元，主要系放缓核心双抗的爬坡节奏及下调非核心管线销售峰值。归母净利润分别为-2.44、7.33、26.80亿元，主要系下调销售收入及上调研发、销售费用率。根据DCF估值，按WACC为8.48%，永续增长率为2%，测算合理股价为206港元，维持“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980454","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0348825331.USD","LU0348766576.USD","IE00B5MMRT66.SGD","LU0348827113.USD","BK1161","LU2399975544.HKD","BK1574","LU0417516571.SGD","LU0348767384.USD","LU0540923850.HKD","LU0348783233.USD","LU1720050803.USD","LU1961090484.USD","LU0417516738.SGD","09926","LU0561508036.HKD","LU0348784397.USD","LU2488822045.USD","LU2778985437.USD","IE00B543WZ88.USD","LU0634319403.HKD","LU1794554557.SGD","LU2476274720.SGD","LU0417516902.SGD","LU0348735423.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181671460","title":"异动解读 | 合作伙伴Summit临床数据未达预期，康方生物盘中大跌9.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181671460","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181671460?lang=zh_cn&edition=full","pubTime":"2026-05-04 09:38","pubTimestamp":1777858720,"startTime":"0","endTime":"0","summary":"康方生物今日盘中股价大跌9.65%，引发了市场的广泛关注。消息面上，此次股价下跌主要受其海外合作伙伴Summit Therapeutics的负面消息拖累。双方合作推进的依沃西单抗一线非小细胞肺癌全球三期临床试验，在中期无进展生存期分析后宣布研究继续进行。市场将此解读为数据未达到即时积极信号，导致Summit Therapeutics股价此前大跌25%。康方生物在节后首个交易日受此情绪传导影响，股价出现明显补跌。根据公司此前披露的财务数据，康方生物全年总收入同比增长显著，但年度净亏损规模仍较大。在今日的生物科技板块中，同行业公司股价表现出现分化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631874546","title":"康方生物：2025年净亏损11.41亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631874546","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631874546?lang=zh_cn&edition=full","pubTime":"2026-04-29 23:01","pubTimestamp":1777474860,"startTime":"0","endTime":"0","summary":"南财智讯4月29日电，康方生物（09926.HK）公告，截至2025年12月31日止年度，公司总收入为30.56亿元人民币，同比增长43.90%；年内亏损为11.41亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293725111963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2476274720.SGD","LU0634319403.HKD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0417516902.SGD","LU0348783233.USD","LU0561508036.HKD","LU0348784397.USD","BK1574","LU2488822045.USD","LU0348825331.USD","LU1961090484.USD","LU2399975544.HKD","09926","LU2476274308.USD","LU0348735423.USD","LU0348767384.USD","LU0540923850.HKD","LU1720050803.USD","LU2778985437.USD","IE00BPRC5H50.USD","BK1161","LU0417516571.SGD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184229118","title":"康方生物(09926)2025年收入显著增长 肿瘤免疫与国际化布局齐头并进","url":"https://stock-news.laohu8.com/highlight/detail?id=1184229118","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184229118?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:59","pubTimestamp":1777474773,"startTime":"0","endTime":"0","summary":"康方生物于2025年度录得总收入人民币30.56亿元，较2024年的21.24亿元增长43.9%，其中商业销售收入达30.33亿元，同比上升约51%，主要受两款肿瘤免疫双抗产品纳入医保所带动。商业授权收入为0.23亿元，较上年度明显下降。毛利为24.04亿元，较2024年的18.35亿元增长31.0%。股本结构上，截至2025年12月31日，公司已发行股本已由2024年的63增至65，主要由于发行新股及股份激励计划等因素所致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物(09926)2025年收入显著增长 肿瘤免疫与国际化布局齐头并进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630320678","title":"美银证券：康方生物(09926)卡度尼利单抗逆季节性录环比增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2630320678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630320678?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:00","pubTimestamp":1777359601,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，康方生物(09926)卡度尼利单抗cadonilimab逆季节性录得环比增长。康方生物2月样本药品销售额为7,130万元人民币(下同)，同比增长319.6%。其中卡度尼利单抗销售额为4,430万元，同比增长249.5%，环比增长9.6%，在农历假期期间仍实现正环比增长。ivonescimab月销售额达2,660万元，持续放量，同比增长517.4%。维持康方生物“买入”评级，目标价为162.8港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","LU0348784397.USD","LU0561508036.HKD","IE00B5MMRT66.SGD","161027","LU0348825331.USD","09926","LU0348827113.USD","LU0348783233.USD","LU0417516738.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU0634319403.HKD","BK1574","BK1161","IE00B543WZ88.USD","LU1961090484.USD","LU2476274308.USD","LU0348766576.USD","LU0540923850.HKD","LU0348767384.USD","LU0417516902.SGD","LU1720050803.USD","LU2399975544.HKD","LU0348735423.USD","LU2778985437.USD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629098100","title":"港股异动 | 康方生物(09926)涨近3% 于AACR 2026大会公布卡度尼利联合疗法一线胰腺癌II期优异数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629098100","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629098100?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:27","pubTimestamp":1776824853,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)涨近3%，截至发稿，涨2.66%，报150.6港元，成交额6.13亿港元。消息面上，据康方生物官微消息，近日，在2026年美国癌症研究协会(AACR)年会上，公司独立自主开发的全球首创 PD-1/CTLA-4 双特异性抗体卡度尼利联合化疗一线治疗晚期胰腺癌(PDAC)的II期临床研究(COMPASSION-26)数据重磅发布。据研究结果显示，卡度尼利联合方案在晚期胰腺癌患者中具有良好的抗肿瘤活性和生存获益，尤其在局部晚期不可手术患者中的中位总生存期(OS)达到23.4个月，中位无进展生存期(PFS)达到11.1个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","LU2476274720.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2488822045.USD","BK4585","LU2476274308.USD","BK4588","LU0561508036.HKD","LU0417516738.SGD","LU0348784397.USD","LU0540923850.HKD","LU1961090484.USD","LU0348735423.USD","VXUS","LU0634319403.HKD","LU0348783233.USD","LU0348766576.USD","LU0417516571.SGD","LU0417516902.SGD","BK1161","LU1794554557.SGD","LU0348767384.USD","IE00B5MMRT66.SGD","BK1574","09926","LU2399975544.HKD","LU0348827113.USD","LU0348825331.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069971","title":"汇添富基金乐无穹旗下港股通创新药ETF汇添富一季报最新持仓，重仓康方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069971","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069971?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:11","pubTimestamp":1776813106,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日汇添富基金旗下乐无穹管理的汇添富国证港股通创新药交易型开放式指数基金公布一季报，近1年净值增长率46.47%。与上一季度相比，该基金前十大重仓股新增荣昌生物；并对康方生物增仓440.9万股，为该基金第一大重仓股；亚盛医药-B等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1961090484.USD","LU0634319403.HKD","BK1574","LU0348766576.USD","LU0348783233.USD","LU0348825331.USD","LU1720050803.USD","LU0348735423.USD","LU2778985437.USD","LU2476274308.USD","LU2476274720.SGD","LU2399975544.HKD","LU0348767384.USD","LU0417516571.SGD","LU0348827113.USD","LU2488822045.USD","BK1161","IE00BPRC5H50.USD","LU0561508036.HKD","LU0540923850.HKD","LU0348784397.USD","LU0417516902.SGD","LU1794554557.SGD","IE00B5MMRT66.SGD","09926","LU0417516738.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629779721","title":"银华基金马君旗下港股创新药ETF银华一季报最新持仓，重仓康方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629779721","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629779721?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:22","pubTimestamp":1776720175,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日银华基金旗下马君管理的银华国证港股通创新药交易型开放式指数基金公布一季报，近1年净值增长率44.51%。与上一季度相比，该基金前十大重仓股新增荣昌生物；并对康方生物增仓32.3万股，为该基金第一大重仓股；亚盛医药-B等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100010042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0348827113.USD","LU0348766576.USD","LU0348767384.USD","LU0417516738.SGD","LU1720050803.USD","LU2488822045.USD","LU0634319403.HKD","LU2476274720.SGD","LU2476274308.USD","BK1574","LU1794554557.SGD","LU0540923850.HKD","LU2399975544.HKD","09926","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","LU0348783233.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0417516571.SGD","LU2778985437.USD","LU1961090484.USD","LU0417516902.SGD","LU0348825331.USD","LU0348784397.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627261720","title":"中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627261720?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","IE00B543WZ88.USD","LU0196878994.USD","HK0000165453.HKD","LU2543165471.USD","LU0417516738.SGD","LU0588546209.SGD","09606","LU0348766576.USD","BK1191","IE00B5MMRT66.SGD","LU1794554557.SGD","HK0000500386.USD","LU2488822045.USD","LU0540923850.HKD","LU0359202008.SGD","LU2778985437.USD","LU0417516902.SGD","06160","LU0348825331.USD","LU0502904849.HKD","06978","LU2097828557.USD","LU0348827113.USD","06990","LU2328871848.SGD","LU0307460666.USD","LU0348784397.USD","LU2476274308.USD","09926","LU1719994722.HKD","LU2097828631.EUR","LU2097828805.USD","159992","LU1770034418.SGD","LU1961090484.USD","IPOS","LU1023057109.AUD","01276","LU0348783233.USD","LU2097828714.EUR","LU0634319403.HKD","LU0561508036.HKD","BK1588","LU2476274720.SGD","LU2399975544.HKD","HK0000252160.HKD","LU0455707207.USD","BK1161","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114779592","title":"康方生物更新2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1114779592","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114779592?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:06","pubTimestamp":1775639206,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年4月8日发布2026年3月股份变动月报。根据公告，截至2026年3月31日，公司注册股本维持在5,000,000,000股，每股面值USD0.00001，注册股本总额为USD50,000，与上月保持一致。公司同时确认于报告期末满足香港联交所对最低公众持股量的要求。该月报由董事夏瑜签署。公司表示将继续遵守香港联交所相关规定，确保公众持股量符合要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625093511","title":"国金证券：维持康方生物(09926)“买入”评级 临床试验陆续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2625093511","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625093511?lang=zh_cn&edition=full","pubTime":"2026-04-07 16:38","pubTimestamp":1775551094,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，康方生物核心产品在国内商业化快速放量、且具备引领全球临床用药迭代的潜力。维持“买入”评级。国金证券主要观点如下：业绩简评2026年3月26日公司发布2025年业绩公告，公司25年实现收入30.56亿元。展望2026年，随着依沃西一线治疗PD-L1阳性NSCLC适应症、卡度尼利疗法一线治疗胃癌和一线治疗宫颈癌适应症，以及派安普利、伊努西和依若奇全部新增纳入国家医保目录，放量有望迎来进一步加速。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624314016","title":"中金：国产创新药产业趋势向好 26年学术领域看点较多","url":"https://stock-news.laohu8.com/highlight/detail?id=2624314016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624314016?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:41","pubTimestamp":1775184094,"startTime":"0","endTime":"0","summary":"中金主要观点如下：研发效率、临床资源优势禀赋，国产创新BD加速、量价齐升NMPA和医药魔方统计显示，2026Q1国内创新药BD总金额超600亿美元，超过2024全年、接近2025全年水平1/2；且平均首付款和平均交易规模均创历史新高。在MNC的积极推动下，多个中国创新资产有望在2026年步入上市申报阶段；基于对国内企业创新能力的认可，多个早期平台化对外合作交易陆续达成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","159992","BK1588","LU0540923850.HKD","BK1515","LU1969619763.USD","01276","LU0359201612.USD","BK1191","LU1720050803.USD","06978","IE00B543WZ88.USD","LU0348735423.USD","LU0417516571.SGD","09926","LU0348827113.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU2543165471.USD","LU0348783233.USD","LU0359202008.SGD","LU1961090484.USD","LU0348766576.USD","LU0561508036.HKD","LU0348825331.USD","09995","06938","LU1303224171.USD","LU0348784397.USD","LU0417516738.SGD","BK1500","LU2399975544.HKD","LU2476274720.SGD","LU1719994722.HKD","LU0634319403.HKD","LU0307460666.USD","LU0588546209.SGD","LU1023057109.AUD","BK1574","LU0359201885.HKD","LU2778985437.USD","BK1583","06160","IE00B5MMRT66.SGD","LU0417516902.SGD","LU1770034418.SGD","LU2488822045.USD","LU1794554557.SGD","LU2328871848.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132166488","title":"异动解读 | 康方生物盘中大涨5.53%，大手买入推动股价上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1132166488","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132166488?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:40","pubTimestamp":1775014801,"startTime":"0","endTime":"0","summary":"康方生物(09926)今日盘中大涨5.53%，引起了市场的广泛关注。消息面上，该股在盘中交易时段出现多次大手买入。根据相关交易数据，在上午不同时间点，康方生物接连出现大额买单，涉及成交量从数万股到近15万股不等，成交金额从数百万到超过两千万港币，这些集中且连续的大手买入直接推动了股价的快速上涨。市场分析认为，机构或大资金的积极买入行为，往往被市场解读为对该公司基本面或未来前景的认可，从而增强了投资者信心，并可能吸引更多资金跟随，共同推升股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371490","title":"【券商聚焦】交银国际维持康方生物(09926)买入评级 预计其2026年起亏损将快速收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371490","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371490?lang=zh_cn&edition=full","pubTime":"2026-03-31 11:08","pubTimestamp":1774926529,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康方生物 2025年商业版图快速扩大，医保覆盖+新品推动下高增速有望延续至2026年：全年产品销售收入同比增长51.5%至30.33亿元，增量主要来自核心产品卡度尼利和首次纳入医保的依沃西。考虑到收入持续高增和费用率改善，该机构预计2026年起亏损将快速收窄。基于2025年业绩下调2026-27年盈利预测，同时基于依沃西的海内外多项进展，将其全球经PoS调整峰值销售预测从116亿美元上调至132亿元。下调DCF目标价至175港元，维持买入评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","BK0276","LU1255011170.USD","LU0307460666.USD","LU1969619763.USD","LU0405327148.USD","LU1328615791.USD","BK1515","09688","LU2399975544.HKD","09926","BK0012","BK1147","01530","LU0634319403.HKD","IE00BPRC5H50.USD","06821","BK1588","02228","01099","BK1100","BK0028","LU0348766576.USD","LU2476274308.USD","BK1161","02367","LU2148510915.USD","LU1303224171.USD","03933","HK0000165453.HKD","BK1191","LU2488822045.USD","600030","01789","LU2495084118.USD","LU1770034418.SGD","BK1593","02268","BK1617","LU0405327494.USD","LU0348783233.USD","IE00B543WZ88.USD","LU1719994722.HKD","BK1583","06030","LU1997245177.USD","06160","BK1564","LU1115378108.SGD","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623159813","title":"北水动向|北水成交净卖出24.67亿 港股ETF及石油股遭抛售 腾讯(00700)再获加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2623159813","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623159813?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:49","pubTimestamp":1774864148,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月30日港股市场，北水成交净卖出24.67亿港元。北水净买入最多的个股是腾讯 、迅策、康方生物。港股通(沪)活跃成交股港股通(深)活跃成交股腾讯获净买入6.08亿港元。消息面上，腾讯自3月26日起重启回购，26日和27日连续回购两天。山东墨龙、中海油分别遭净卖出509万、7064万港元。北水资金抛售港股ETF，盈富基金、南方恒生科技、恒生中国企业分别遭净卖出38.45亿、13.38亿、11.83亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0572940350.SGD","IE00BZ08YT58.USD","LU1813983027.USD","LU0449509016.USD","LU0819123356.HKD","BK1528","BK4570","IE00B0JY6N72.USD","SG9999002463.SGD","IE00B3M56506.USD","80883","LU0786609619.USD","LU0823397103.USD","IE00BQXX3C00.GBP","LU1366334578.USD","LU1439103000.SGD","LU1785774172.SGD","IE0008368742.USD","LU0737861772.HKD","LU1044874839.SGD","LU1048588211.SGD","LU2051468812.USD","SG9999014674.SGD","LU1868837565.USD","BK1586","LU2279701549.SGD","SG9999018865.SGD","LU0231483743.USD","LU0049112450.USD","SG9999001903.USD","LU0128522744.USD","LU0143863198.USD","LU1051769294.HKD","LU1974910355.USD","IE00B5MMRT66.SGD","LU0067412154.USD","LU1196710195.USD","LU0594300179.USD","LU1282649141.HKD","LU1188198961.HKD","LU1102505762.USD","BK1526","LU0345769631.USD","HK0000320264.USD","LU0972618739.USD","LU0106259558.USD","LU0784639295.USD","LU1794554557.SGD","LU0106959298.USD","LU1303224171.USD","LU1807302812.USD","LU0828237510.HKD","LU2237443465.HKD","LU0039217434.USD","LU0634319403.HKD","LU1814569148.SGD","SG9999006597.SGD","LU0048580855.USD","LU0531971595.HKD","IE0003851619.USD","LU0577902538.SGD","SG9999001069.SGD","LU0456842615.SGD","IE00B031J352.USD","LU0229945570.USD","LU0348825331.USD","LU2097828557.USD","LU0675040207.SGD","LU3063872942.SGD","LU0117841782.USD","LU1769817096.USD","LU0396098781.USD","LU0328353924.USD","LU1719994722.HKD","BK1516","LU0737861699.HKD","LU0823426308.USD","LU2362540622.SGD","LU2087589342.USD","LU1691799644.USD","LU0577902298.EUR","LU0531970944.HKD","LU0048597586.USD","LU0140636845.USD","SG9999001226.SGD","SG9999014906.USD","LU0293314216.USD","LU0819121731.USD","LU0326950275.SGD","SG9999002562.SGD","LU0345775950.USD","LU0251144936.SGD","LU0738912210.USD","LU2039709279.SGD","LU0149721374.USD","LU2317271919.USD","LU0823041008.USD","LU0509642566.USD","LU1880383440.USD","HK0001040168.HKD","BK1238","LU1688375341.USD","HK0000306701.USD","SGXZ90724238.SGD","LU1504937902.USD","LU0359201612.USD","LU0127658192.USD","BK4504","LU0577902371.SGD","SG9999001689.USD","LU0320764599.SGD","LU0196878994.USD","IE00BZ08YS42.EUR","IE00B031HY20.USD","LU0345769128.USD","LU0348816934.USD","LU2152927971.USD","LU0320764755.SGD","LU1868838027.USD","LU0287142896.SGD","LU1226288253.USD","LU2449936058.SGD","BK1608","LU0791591158.USD","HK0000352382.USD","LU2257852520.SGD","LU0107464264.USD","SG9999002828.SGD","LU0918141887.USD","LU0348788117.USD","LU0047713382.USD","IE00B29SXG58.USD","LU0541501648.USD","LU0823039010.USD","LU0348814723.USD","BK1095","LU1224709979.USD","BK4077","BK1531","BK4581","LU1226287529.USD","SG9999000327.SGD","LU2362541273.HKD","HSTECH","LU2133065610.SGD","LU0797268264.HKD","LU0307460666.USD","HK0000320223.HKD","LU0210526637.USD","LU2045819591.USD","LU0259732245.USD","LU0588545904.SGD","LU1328615791.USD","LU1720050803.USD","LU0043850808.USD","LU0359202008.SGD","LU1960683339.HKD","HK0000352291.HKD","LU1956131251.USD","LU0862451837.USD","LU2242644610.SGD","LU0708995153.HKD","LU0165289439.USD","LU1152091168.USD","LU1769817179.HKD","LU2097828714.EUR","LU0254981946.USD","LU0708995583.HKD","LU1568876335.HKD","LU1993786604.SGD","LU0823397285.USD","IE00BZ08YR35.GBP","IE0034224299.USD","LU0878005551.USD","LU1282649067.USD","LU0499858602.USD","LU0345776255.USD","LU0052750758.USD","LU0414403682.SGD","LU0203345920.USD","LU1439102457.SGD","LU0314109678.HKD","LU0456827905.SGD","LU0455707207.USD","LU0918141705.HKD","LU0516423174.USD","LU0880133367.SGD","LU0865486749.SGD","LU2125910849.SGD","LU2247934214.USD","LU0029875118.USD","LU0072913022.USD","LU0210533765.USD","LU2498475776.HKD","LU0588545490.SGD","IE0008368411.USD","LU1224444064.USD","LU0203347892.USD","LU0289960550.SGD","IE00B031HW06.USD","LU1226287792.SGD","LU1481107354.HKD","HSI","LU2778985437.USD","BK1609","LU1105468828.SGD","LU1044875133.USD","LU0469268626.HKD","LU2023250504.SGD","SG9999004220.SGD","LU0011963245.USD","LU0633140727.USD","LU0164865239.USD","SG9999015952.SGD","LU0211977185.USD","LU0164872284.USD","SG9999007991.SGD","SG9999017495.SGD","LU0642271901.SGD","LU1725190679.HKD","LU0054450605.USD","LU0577902611.USD","LU0261947096.USD","LU2125910500.SGD","LU0359201885.HKD","LU1328277881.USD","IE0001KFT4U8.USD","LU0890818403.SGD","LU0821914370.USD","SG9999015986.USD","00700","HTCD.SI","LU0132412106.USD","LU2097828805.USD","LU0070217475.USD","LU0791590937.USD","LU0588546209.SGD","HK0001040143.USD","LU2226246903.HKD","SG9999003461.SGD","LU0456846285.SGD","LU0823426480.USD","LU0979878070.USD","SG9999001051.SGD","BK1610","LU0117844026.USD","LU1718418525.SGD","LU1044876610.USD","LU1323998911.USD","LU1366334651.USD","LU1655091459.SGD","IE00B0169N27.USD","LU2148510915.USD","LU0048388663.USD","LU0651946864.USD","LU0244354667.USD","LU0054237671.USD","LU0608807946.USD","LU1226287875.USD","SG9999014880.SGD","IE00B543WZ88.USD","LU0228367735.SGD","LU0329678170.USD","LU0348783233.USD","LU1808992512.USD","LU0417516571.SGD","BK4585","LU1831875114.USD","LU0149534421.HKD","LU2265009873.SGD","LU0106252389.USD","LU0823038988.USD","IE00B0169L03.USD","LU0593848301.USD","LU0211331839.USD","IE00B067MR52.USD","BK1589","LU1251922891.USD","IE0003795394.USD","LU1629966141.USD","LU0985320562.USD","LU1023057109.AUD","LU1196710864.SGD","LU0329678337.USD","LU1226288170.HKD","LU0449515922.USD","LU0348827113.USD","LU1008478684.HKD","SGXZ31699556.SGD","LU1770036033.HKD","LU0605514214.HKD","LU0029874905.USD","LU1951186391.HKD","LU0823413660.USD","LU1282648689.USD","IE00BQXX3D17.EUR","LU1051768304.USD","LU0577902454.USD","HK0000914660.USD","GB00BDT5M118.USD","LU0868486357.SGD","BK1502","LU0348805143.USD","LU0828238088.HKD","LU0683595622.HKD","LU0700851271.USD","LU1211504680.USD","LU0463099449.HKD","LU2237443382.USD","IE00B8HQ1Z84.USD","LU0417516738.SGD","IE0008369823.USD","LU0431992006.USD","LU0370786039.SGD","IE0032431581.USD","LU0572944931.SGD","LU0173614495.USD","LU0898667661.SGD","IE0009570106.USD","LU0873338254.USD","HK0000306685.HKD","LU0540923850.HKD","LU1242518931.SGD","SGXZ81514606.USD","LU0608807433.USD","SG9999015945.SGD","LU0327786744.USD","LU2237443895.HKD","LU2399975544.HKD","LU2476274720.SGD","LU0651947912.USD","LU1196710351.USD","IE00BGV7N243.SGD","LU1064131003.USD","LU0051755006.USD","SG9999018857.SGD","LU1235295612.USD","LU0163747925.USD","LU1810669033.SGD","LU0417516902.SGD","LU1917777945.USD","TCEHY","LU0143863784.USD","LU1048484197.HKD","LU0589944569.HKD","SG9999001846.SGD","SGXZ51526630.SGD","IE0032834883.USD","LU0543330483.HKD","BK1618","LU1642822792.SGD","LU0192582467.USD","LU1242518857.USD","LU0264606111.USD","LU0543330566.HKD","SG9999014914.USD","SG9999013353.USD","SG9999000418.SGD","SG9999001093.SGD","LU0228659784.USD","LU0326948709.USD","LU0080751232.USD","LU2097828474.EUR","LU0164880469.USD","IE00BPRC5H50.USD","BK4550","LU0672654166.SGD","LU2008162690.USD","LU1981816686.USD","LU0061477393.USD","LU0488056044.USD","LU0499858438.USD","LU2237443549.SGD","SG9999015978.USD","LU1568876251.USD","LU1675838814.USD","SG9999000459.SGD","LU0516422366.SGD","LU0169518387.USD","LU0823413587.USD","SG9999014898.SGD","LU1046422090.SGD","LU0516422440.USD","LU0181495838.USD","LU0049853897.USD","LU2237443622.USD","LU0084288322.USD","LU1961090484.USD","LU0516422952.EUR","LU1064130708.USD","BK1607","LU0128522157.USD","LU0607220059.USD","LU0650527681.SGD","LU0588545730.USD","LU1282649810.SGD","LU2097828631.EUR","LU1883866441.USD","LU0348784397.USD","LU0348723411.USD","LU0188438112.USD","LU0594300419.USD","SGXZ99366536.SGD","LU0886674414.USD","LU1733274390.USD","IE0031814852.USD","LU1316542783.SGD","LU0882747503.HKD","LU0384037296.USD","LU1515016050.SGD","LU1880383366.USD","09926","LU1868837722.USD","LU0315178854.USD","BK1614","LU1804176565.USD","LU0235996351.USD","IE00BQXX3F31.USD","LU0072462343.USD","LU0348783662.USD","LU0862451753.SGD","LU0501845795.SGD","LU0856984785.SGD","LU2237443978.SGD","LU0502904849.HKD","IE00B8L5B284.USD","LU1048596156.SGD","BK4588","LU1226288097.SGD","LU0648948544.HKD","BK1517","LU0823040885.USD","BK1521","LU1734074674.USD","LU0096374516.USD","03033","LU0214875030.USD","LU2476274308.USD","LU0210527791.USD","LU1282651121.HKD","LU2177674079.SGD","LU2106854487.HKD","LU2462611646.USD","LU0611395673.USD","LU2362541513.USD","SG9999006514.SGD","LU0541502299.USD","LU0320764243.SGD","BK1591","LU0831103253.SGD","HK0000914686.HKD","LU0828237940.HKD","BK1163","LU0516423091.SGD","LU0572939691.SGD","LU0348735423.USD","LU0175139822.USD","LU0878004406.USD","LU0633140560.USD","LU2251237488.HKD","LU1733274473.HKD","LU0441854154.USD","BK1615","LU1152091754.HKD","LU0269904917.USD","LU1282651048.USD","LU0261950983.USD","LU0561508036.HKD","LU1770034418.SGD","LU2251237306.USD","IE00BF5LJ272.USD","LU1102505929.USD","IE0003895053.USD","IE00B97KM107.HKD","LU0871576103.HKD","LU2293587155.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623671793","title":"大行评级丨瑞银：康方生物去年下半年业绩逊于预期，目标价降至173.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623671793","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623671793?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:47","pubTimestamp":1774838822,"startTime":"0","endTime":"0","summary":"瑞银发表研报指，康方生物去年下半年收入按年增长50%至16.4亿元，较该行及市场预期低；净亏损由前一年同期的2.76亿元扩大至5.43亿元，同样逊于该行及市场预期。2025年全年收入按年增长44%至31亿元，净亏损由2024年的5亿元扩大至11亿元。基于2025下半年业绩，该行下调2026及2027年收入预测，并上调销售及研发开支预测，导致同期每股盈利预测由1.14元及2.73元，下调至亏损0.12元及盈利1.06元；目标价由196.5港元下调至173.4港元，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260330/32110854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0498},{"period":"3month","weight":0.3179},{"period":"6month","weight":0.1898},{"period":"1year","weight":0.5398},{"period":"ytd","weight":0.1814}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0437},{"period":"3month","weight":-0.025},{"period":"6month","weight":-0.0011},{"period":"1year","weight":0.1567},{"period":"ytd","weight":0.0228}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.005105},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}